Alnylam Pharmaceuticals, Inc. (ALNY) financial statements (2021 and earlier)

Company profile

Business Address 675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,8741,8341,9261,3421,5361,7211,927
Cash and cash equivalents4974975814685479231,136
Short-term investments1,3781,3371,345874989798791
Restricted cash and investments2000000
Receivables102796976434831
Inventory, net of allowances, customer advances and progress billings75677768565541
Inventory75677768565541
Other undisclosed current assets5605758899807465
Total current assets:2,6152,5552,1601,5851,7161,8972,064
Noncurrent Assets
Operating lease, right-of-use asset241245230221221223 
Property, plant and equipment465445439430425396372
Restricted cash and investments41252725151548
Other noncurrent assets45382019181010
Other undisclosed noncurrent assets  498   223
Total noncurrent assets:7927531,214695679644653
TOTAL ASSETS:3,4073,3073,3742,2802,3952,5422,716
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities408323237224247217210
Accounts payable52282640503971
Accrued liabilities356295211183197178139
Deferred revenue1271151088678107 
Debt 3233292828 
Contract with customer, liability89
Other undisclosed current liabilities50106   29
Total current liabilities:585480384339353353329
Noncurrent Liabilities
Long-term debt and lease obligation48429728227627627630
Long-term debt, excluding current maturities191     30
Operating lease, liability293297282276276276 
Liabilities, other than long-term debt263282300315328305323
Deferred revenue225266282306318296 
Contract with customer, liability314
Other liabilities38161999910
Other undisclosed noncurrent liabilities1,0581,0331,008   277
Total noncurrent liabilities:1,8061,6121,590591604582631
Total liabilities:2,3912,0921,975930956935959
Stockholders' equity
Stockholders' equity attributable to parent1,0161,2151,4001,3501,4391,6071,757
Common stock1111111
Additional paid in capital5,6445,5935,5205,2905,2015,0915,034
Accumulated other comprehensive loss(44)(37)(33)(32)(37)(34)(36)
Accumulated deficit(4,585)(4,342)(4,089)(3,909)(3,727)(3,451)(3,242)
Total stockholders' equity:1,0161,2151,4001,3501,4391,6071,757
TOTAL LIABILITIES AND EQUITY:3,4073,3073,3742,2802,3952,5422,716

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues16412610499727045
Cost of revenue
(Cost of Goods and Services Sold)
(23)(22)(20)(13)(12)(5)(4)
Gross profit:1411048486606540
Operating expenses(335)(329)(283)(296)(358)(281)(277)
Operating loss:(194)(225)(199)(210)(298)(216)(236)
Nonoperating income (expense)(49)(27)212921718
Investment income, nonoperating12357109
Other nonoperating income (expense)(22)(1)452314(3)(0)
Interest and debt expense(29)(29)(27)    
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes84   (1)  
Loss from continuing operations before equity method investments, income taxes:(188)(281)(205)(182)(277)(209)(219)
Other undisclosed income (loss) from continuing operations before income taxes(56)2927 1  
Loss from continuing operations before income taxes:(244)(252)(178)(182)(277)(209)(219)
Income tax expense (benefit)0(1)(1)(1)00(1)
Net loss available to common stockholders, diluted:(244)(253)(179)(182)(276)(209)(219)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(244)(253)(179)(182)(276)(209)(219)
Other comprehensive income (loss)(6)(4)(1)4(2)1(3)
Comprehensive loss, net of tax, attributable to parent:(250)(257)(180)(178)(278)(207)(222)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: